Recombinant Newcastle disease virus (lentogenic strain rClone30) expressing IL-2 demonstrate good antitumor efficiency in lung cancer model
Prepared by:
Dr. Lubna Muhi Rasoul/College of science, department of biology, university of Baghdad
Abstract
In this study we have investigated the antitumor effect of genetically engineered Newcastle disease virus strains expressing IL-2 (rClone30–IL-2) for lung cancer therapy. We have used mice Lewis Lung Carcinoma cell line (LLC) to create a tumor model in 45 C57 female mice, mice were divided into 3 groups each group contains 15 mice for the treatment with rclone30-IL-2, rclone30 and PBS, respectively. In vitro studies showed that NDV could efficiently infect tumor cells and express IL-2. Animal studies showed that rClone30 expressing IL-2 was highly effective in inhibiting Lung carcinoma tumors, with the mean tumor volume of 291.255 mm3 for rClone30 -IL-2 comparing to 763.068 mm3 of rClone30 group, and 1101.68 mm3 of phosphate-buffered saline group. For the survival study, rClone30–IL-2 increased the survival rate (12) of tumor bearing mice in eClone30-IL-2 group versus (7) of 15 in Clone30 group, and 0/15 in phosphate-buffered saline group, respectively. These results suggest that NDV expressing IL-2 gene was highly significant in inhibiting lung tumors in mice and enhancing the antitumor ability of Newcastle disease virus. The results of this study showed promising results for rClone30-IL-2 and laid a foundation for the treatment of lung cancer.